Aandelen in “Fabricage van farmaceutische preparaten”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Fabricage van farmaceutische preparaten”

15:00 · Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform · Persbericht

15:00 · Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform · Persbericht

14:00 · Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) · Persbericht

14:00 · Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD) · Persbericht

12:00 · Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate · Persbericht

29/03 · Eli Lilly sluit miljardendeal rond ontwikkeling medicijnen met AI · Tijd.be (€)

De Amerikaanse farmagroep Eli Lilly sluit een deal van 2,75 miljard dollar om medicijnen te ontwikkelen op basis van artificiële intelligentie.

28/03 · Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity · Persbericht

28/03 · Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting · Persbericht

28/03 · Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session · Persbericht

28/03 · ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis · Persbericht

28/03 · Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

28/03 · uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

28/03 · Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

27/03 · AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting · Persbericht

27/03 · Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis · Persbericht

27/03 · Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma · Persbericht

26/03 · Galapagos Announces Nomination of Gino Santini to its Board of Directors · Persbericht

26/03 · Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Raad van Bestuur · Persbericht

26/03 · Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings · Persbericht

26/03 · Galapagos publiceert 2025 jaarverslag en kondigt de Gewone (jaarlijkse) en Buitengewone Algemene Vergaderingen aan · Persbericht

26/03 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR · Persbericht

Mijn selecties